Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062408 | 1.00 | CCR2 (0.41) | CCR2HPGDALDH1A1MAPTKMT2A | |
| SCHEMBL1080974 | 0.82 | CCR2 (0.58) | CCR2HPGDALDH1A1MAPTKMT2A | |
| SCHEMBL1062410 | 0.77 | CCR2 (0.70) | CCR2 | |
| SCHEMBL1080108 | 0.77 | CCR2 (0.70) | CCR2 | |
| SCHEMBL3318233 | 0.76 | HPGD (0.37) | CCR2HPGDALDH1A1TSHRPOLB | |
| SCHEMBL8312942 | 0.73 | ALDH1A1 (0.42) | CCR2ALDH1A1KDM4E | |
| SCHEMBL9162699 | 0.73 | ALDH1A1 (0.42) | CCR2ALDH1A1KDM4E | |
| SCHEMBL4639716 | 0.73 | CCR2 (0.36) | CCR2 | |
| SCHEMBL5172985 | 0.72 | ALOX15 (0.44) | CCR2KMT2APOLB | |
| SCHEMBL3316845 | 0.72 | ALOX15 (0.44) | CCR2KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896036-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-8076323-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-13 | — | — | US | disclosed |
| US-20110003792-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| US-7803794-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20100016286-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016286-A1 | Anti-Inflammatory Agents | TNF, LTC4S, IL6 | CCR2 54/4885HPGD 846/4885ALDH1A1 1034/4885 |
| US-20110003792-A1 | ANTI-INFLAMMATORY AGENTS | TNF, LTC4S, PTGS1 | CCR2 45/4885HPGD 766/4885ALDH1A1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.